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Abstract
Background: Increased resistance to antimicrobial agents is a characteristic of many bacteria growing in biofilms
on for example indwelling urinary catheters or in intracellular bacterial reservoirs. Biofilm-related infections caused
by multidrug-resistant bacteria, such as extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, are a
major challenge. The aim of this study was to investigate if a carbon monoxide-releasing molecule (CORM-2) has
antibacterial effects against ESBL-producing uropathogenic E. coli (UPEC) in the biofilm mode of growth and
following colonization of host bladder epithelial cells.
Results: The effect of CORM-2 was examined on bacteria grown within an established biofilm (biofilm formed for 24 h
on plastic surface) by a live/dead viability staining assay. CORM-2 (500 μM) exposure for 24 h killed approximately 60 %
of the ESBL-producing UPEC isolate. A non-ESBL-producing UPEC isolate and the E. coli K-12 strain TG1 were also
sensitive to CORM-2 exposure when grown in biofilms. The antibacterial effect of CORM-2 on planktonic bacteria was
reduced and delayed in the stationary growth phase compared to the exponential growth phase. In human bladder
epithelial cell colonization experiments, CORM-2 exposure for 4 h significantly reduced the bacterial counts of an
ESBL-producing UPEC isolate.
Conclusion: This study shows that CORM-2 has antibacterial properties against multidrug-resistant UPEC under biofilm-
like conditions and following host cell colonization, which motivate further studies of its therapeutic potential.
Keywords: Carbon monoxide releasing molecule, CORM-2, Extended-spectrum β-lactamase, Uropathogenic Escherichia
coli, Biofilm
Background
Biofilm is defined as bacteria enclosed in a self-produced
polymeric matrix adherent to a biotic or abiotic surface
[1]. Escherichia coli (E. coli) growing in biofilm display a
development in several steps. Attachment is first mediated
by flagella, type 1 fimbriae, curli and polysaccharides
followed by early development of biofilm architecture and
a maturation step [2]. Bacterial biofilms are more resistant
to the effects of an antimicrobial agent than planktonic
bacteria [3]. Slow growth rates, induction of biofilm-
specific phenotypes and stress response activation as well
as restricted antibiotic penetration by biofilm architecture
have been proposed to explain the reduced susceptibility
[3]. Biofilm formation on indwelling devices such as urin-
ary catheters increases the risk of urinary tract infections
(UTIs) and results in considerable antibiotic use [4]. Uro-
pathogenic isolates of E. coli (UPEC) are the most fre-
quent isolate in catheterized patients with UTI symptoms
[5], and biofilm producing UPEC are also more frequent
among strains causing UTI relapse [6]. Moreover, it has
recently been recognized that UPEC may form biofilm-
like structures on and inside bladder epithelial cells [7, 8].
If UPEC invade the urothelial cells they may rapidly
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replicate and subsequently aggregate into biofilm-like
intracellular bacterial communities (IBC). In the late stage
of IBC formation, the IBCs break open causing flux of
bacteria from the superficial bladder facet cells into the
bladder lumen allowing for invasion of other bladder cells
[7, 9]. UPEC have also been shown to establish small clus-
ters of more persistent intracellular reservoirs within the
underlying basal epithelium [10]. Intracellular reservoirs
of UPEC are believed to go undetected by standard urine
culture, be protected from host defense mechanisms and
persist despite antibiotic therapy [9]. Interestingly, emer-
ging data suggest that UPEC persisting within intracellular
reservoirs may have a role in development of recurrent
and chronic UTIs [8, 9, 11]. Commonly used antibiotic
treatments failed to eradicate UPEC growing internalized
within bladder epithelial cells, by a proposed combination
of biofilm formation, metabolically quiescent bacteria and
bladder urothelial barriers [12, 13]. Thus, treatment of
biofilm-related UTI is a challenge and particularly if
caused by multidrug-resistant UPEC isolates.
Multidrug-resistant extended-spectrum β-lactamase
(ESBL)-producing E. coli have disseminated worldwide
and a main reason for mortality caused by these bacteria
is inadequate initial antimicrobial therapy [14]. ESBL-
producing Enterobacteriaceae spp. have genes that code
for the ESBL enzyme and different ESBL enzyme vari-
ants (TEM, SHV, CTX-M) have been identified. CTX-M
β-lactamases confer resistance to third generation ceph-
alosporins, like cefotaxime, and often against other
classes of antibiotics such as fluoroquinolones [15]. Dis-
semination of ESBL-producing bacteria occurs by hori-
zontal transfer of plasmids (mainly CTX-M plasmids) or
clonal spread [16]. The CTX-M-15 dominance around
the world is due to dissemination of the virulent UPEC
clone ST131 [17]. Studies indicate that the close contact
between cells during biofilm conditions facilitates plas-
mid transfer by conjugation, a phenomenon that may
increase the development of multidrug resistance in
biofilm [18].
New treatment strategies for multidrug-resistant bac-
teria may include approaches with more penetrant anti-
microbials with activity against non-growing bacteria or
biofilm. Carbon monoxide (CO) is a small gaseous mol-
ecule with anti-inflammatory and antimicrobial proper-
ties that is able to penetrate cell membranes [19]. Metal
carbonyl compounds, commonly known as CO-releasing
molecules or CORMs, that release CO in a controlled
manner have been developed for therapeutic applica-
tions [20]. Antibacterial effects of ruthenium-based car-
bonyls (CORM-2 and CORM-3) are reported in E. coli
K-12 strains, Staphylococcus aureus and Pseudomonas
aeruginosa [21–23]. CORM-3 has been shown to rapidly
deliver CO to the intracellular part of the bacteria and
to inhibit respiration by reacting with cytochrome bd
and bo’ [22]. However, the activity of CORMs is not re-
stricted to impairment of the aerobic respiratory chain,
as these compounds are also effective in near-anaerobic
conditions [21]. Another proposed mechanism for the
antibacterial effect of CORM-2 is generation of intracel-
lular reactive oxygen species that cause DNA damage
and death [24]. Many genes related to biofilm formation
were modified by CORM-2 as shown by whole-genome
transcription profiling of a non-pathogenic E. coli K-12
strain [25]. We have recently shown that CORM-2 has
bactericidal effects on planktonic multidrug-resistant
ESBL-producing UPEC isolates [26], but it is not yet
known if CORM-2 will be effective against ESBL-
producing UPEC isolates in biofilms.
The aim of the present work was to investigate the
antibacterial effects of CORM-2 on ESBL-producing
UPEC in the biofilm mode of growth and following
colonization of host bladder epithelial cells.
Methods
Bacterial isolates and strains
Four ESBL-producing UPEC isolates (designated ESBL1,
6, 7, 9) and four non-ESBL-producing UPEC isolates
(designated UPEC 2, 3, 4, 5) were obtained from the De-
partment of Microbiology at Örebro University hospital,
Sweden. The UPEC isolates were recovered from urine
of standard care patients with indwelling urinary cathe-
ters and symptoms of UTI. The identity of the patients
was anonymized prior to further analysis of the bacterial
isolates. Ethical approval was not required for this study
as no analysis of human subjects, human material or hu-
man data were made. Antimicrobial susceptibility testing
was performed using methods recommended by the
Swedish Reference Group for Antibiotics (www.sls.se/
RAF) and the subcommittee on methodology (Nordi-
cAST) (www.nordicast.org). The ESBL-producing iso-
lates were characterized regarding CTX-M type as
previously described [27]. The E. coli clone ST131 was
detected using two ST131-specific pabB SNP assays by
real-time PCR as previously described [28]. The CTX-M
types, clonal group ST131 and the antibiotic susceptibil-
ity of the ESBL-producing isolates are shown in Table 1.
The commensal E. coli K-12 strain TG1 carrying a F-
conjugative plasmid that promotes biofilm formation
[29] was used as a positive control strain for biofilm for-
mation. TG1 and the commensal E. coli K-12 strain
MG1655 were used from laboratory stocks.
Analysis of biofilm formation
Overnight cultures in Difco Luria-Bertani (LB) broth
(Lennox, Becton Dickinson, Franklin Lakes, USA) were
used to inoculate (at 0.1 %) fresh minimal salt (MS)
medium [21] on agitation to an optical density (OD620)
of approximately 0.05. The bacteria were seeded into 96-
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well plastic plates (Nunc C96 Microwell plate, Nunc A/
S, Roskilde, Denmark) and after 6 h at 37 °C exposed to
sub-inhibitory concentrations (100 or 250 μM) of
CORM-2 ([Ru(CO)3Cl2]2 (Sigma-Aldrich, St. Louis, MO,
USA) or left untreated. After an additional 18 h of incu-
bation under static conditions at 37 °C, biofilm forma-
tion was quantified by the crystal violet method as
previously described [25]. The absorbance at 540 nm was
measured by spectrophotometer (Thermo Labsystems,
Multiscan Ascent).
Live/dead viability staining assay
Overnight cultures of biofilm producing strains were
grown on eight-well chambered cover glasses (Lab-Tek,
Rochester NY) for 24 h at 37 °C. Planktonic bacteria
were removed by gentle washing and the remaining bio-
film was exposed to CORM-2 (500 μM), cefotaxime
(0.512 μg/ml (Sigma-Aldrich), corresponding to 4 x MIC
for UPEC isolate 2) or vehicle (DMSO 2.5 % or sterile
water) for 24 h at 37 °C. MIC for CORM-2 has previ-
ously been reported to be 500 μM in E. coli [21]. There-
after, the biofilms were washed with 0.85 % NaCl and
incubated with a live/dead viability staining assay
(BacLight, Life Technologies, Leiden, The Netherlands)
according to kit instructions. Biofilm images were ob-
tained using a Leica TCS confocal laser scanning micro-
scope (Leica Microsystems, Heidelberg GmbH, Wetzlar,
Germany). The ratio of dead bacteria (expressed as a
percentage) was calculated by manual counting of four
randomly selected quadrants (in total covering ¼ from
each image) from a representative part of each well.
Bacterial viability under planktonic growth conditions
Overnight LB-cultures were used to inoculate (at 0.1 %)
fresh MS-medium. In experiments representing the expo-
nential growth phase, cultures were grown to an OD620 of
approximately 0.1 to reach early exponential phase. The
bacterial concentration of the initial inoculums used in
these experiments was approximately 107-108 CFU/ml. In
experiments representing the stationary growth phase,
cultures were grown with aeration at 37 °C for approxi-
mately 14 h. The bacterial concentration of the initial in-
oculums used in these experiments was approximately109
CFU/ml. The bacteria were treated with CORM-2 (500
μM), DMSO (controls) or cefotaxime (0.512 μg/ml) for 4
and 24 h. After treatment, the bacterial viability was deter-
mined by plating serial dilution on TSA plates
followed by counting the CFU numbers on overnight
cultures at 37 °C. Bacterial CFU/ml was determined
by using the mean from two dilutions.
Human bladder epithelial cells
The human bladder epithelial cell line 5637 (ATCC
HTB-9; American Type Culture Collection Manassas,
USA) was grown in Dulbecco’s Modified Eagle medium
(Sigma-Aldrich) supplemented with 10 % fetal bovine
serum, 2 mM L-glutamine, 1 mM non-essential amino
acids, 100 U/ml penicillin and 100 μg/ml streptomycin
(all from Invitrogen, Paisley, UK) in a humidified incuba-
tor at 37 °C with 5 % CO2.
Bacterial viability following colonization of host bladder
cells
Overnight LB-cultures of ESBL-producing isolate 6, 7
and 9 were grown at 37 °C in static LB-broth to facilitate
induction of type-1 fimbriae expression [30]. The 5637
bladder epithelial cells were grown in 24-wells until con-
fluent and infected with bacteria in DMEM supple-
mented with 2 % fetal bovine serum, 2 mM L-glutamine
and 1 mM non-essential amino acids. A multiplicity of
infection (MOI) of approximately 20 bacteria per host
cells was used. The 24 well plates were centrifuged at
600 x g for 10 min to facilitate the attachment of bac-
teria to epithelial cells followed by incubation for 2 h. A
gentamycin protection assay was used to support intra-
cellular growth of UPEC as previously described [12].
Table 1 Characteristics of the clinical isolates
Isolate CTX-M subgroup CTX-M type ST131 clone Antibiotic resistance
ESBL 1 CTX-M -9 CTX-M-24 - CTX, CAZ, CTB, CIP, GEN, MEL, TMP
ESBL 6 CTX-M -1 CTX-M-15 + CTX, CAZ, CTB, CIP, TMP
ESBL 7 CTX-M -1 CTX-M-15 + CTX, CAZ, CIP, MEL, TMP





Antibiotic resistance of ESBL-producing isolates (ESBL) and non-ESBL-producing UPEC isolates (UPEC) isolated from urine of patients with UTI. The CTX-M
subgroup, CTX-M type and sequence type (ST) 131 are indicated for the ESBL-producing isolates
Abbreviations: cefotaxime (CTX), ceftazidime (CAZ), ceftibuten (CTB), ciprofloxacin (CIP), gentamicin (GEN), mecillinam (MEL), nitrofurantoin (NIT),
trimethoprim (TMP)
asusceptibility tested for NIT, MEL, TMP, CTX, CIP
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Briefly, cells were incubated with 100 μg/ml of gentamy-
cin in DMEM for 2 h to kill extracellular bacteria. Fol-
lowing washes with PBS, the cells were incubated with
DMEM containing a submaximal concentration of gen-
tamycin (10 μg/ml) for another 14 h to limit potential
leak of gentamycin into the bladder cells. Cell layers
were washed and exposed for 4 h to CORM-2 (250 and
500 μM), cefotaxime (0.512 μg/ml) or controls (DMSO
or Ru(DMSO)4Cl2). Ru(DMSO)4Cl2 (Strem chemicals
Inc, Newburyport, MA, USA) is a negative control for
CORM-2 where the CO groups have been replaced by
DMSO. The host cell viability and adherence were
checked throughout the experiments. After incubation,
the cells were washed, lysed with 0.5 % Triton X-100
and serially diluted and counted by plating on TSA agar
plates as described before.
Immunofluorescence of UPEC in the presence of host
bladder epithelial cells
Bladder 5637 cells were seeded onto well glass chamber
slides (SPL Lifesciences Co., Ltd., Pocheon-city, Gyeonggi-
Do, Korea), grown to subconfluency and infected with
ESBL isolates as described above. After the incubation
with gentamycin (totally 16 h), the cells were washed with
PBS and fixed for 10 min in 4 % paraformaldehyde. Cells
were washed and incubated with 1 % bovine serum albu-
mine (BSA) to block unspecific binding of the antibodies.
Extracellular bacteria were labelled by incubation with a
goat polyclonal anti-E. coli antibody (Abcam, Cambridge,
UK) diluted 1:500 in PBS with 1 % BSA for 60 min at
room temperature (RT), washed and then incubated with
a secondary donkey anti-goat IgG-DyLight549 conjugated
antibody (Jackson ImmunoResearch Europe Ltd., Suffolk,
UK) (red fluorescence) diluted 1:500 (in PBS with 1 %
BSA) for 90 min at RT. In order to label intracellular bac-
teria the host cells were permeabilized with 0.5 % Triton
X-100 for 10 min, washed and reprobed with the goat
anti-E. coli antibody for 60 min. After wash, the bacteria
were stained with a secondary rabbit anti-goat IgG-FITC
conjugated antibody (Sigma-Aldrich) (green fluorescence)
diluted 1:400 (in PBS with 1 % BSA) for 100 min at RT.
Samples were mounted with Vectashield Mounting media
(Vector Laboratories Inc., Burlingame, CA, USA) contain-
ing 4′, 6-diamidino-2-phenylindole (DAPI) for staining of
nuclei. Bacteria that stained both red and green were
scored as adherent extracellular bacteria, while those that
stained only green were scored as intracellular bacteria.
Images were obtained and processed using an Olympus
BX60 fluorescence microscope equipped with an Olympus
DP71 camera and Adobe Photoshop software.
Statistical analysis
Data are expressed as mean ± SEM. Differences between
two groups were assessed by the unpaired two-tailed
Students t-test or by the one sample t-test when controls
were normalized to 1. One-way ANOVA followed by
Bonferroni test was used for multiple comparisons. Re-
sults were considered statistically significant at p < 0.05.
n = number of independent experiments.
Results
Effect of CORM-2 on biofilm formation
A detectable basal biofilm formation (A540 > 0.1) was
found in ESBL-producing isolate 1, UPEC isolates 2 and
3 and the non-pathogenic E. coli K-12 strains MG1655
and TG1 (Table 2). Only these isolates were used for fur-
ther biofilm studies. A sub-inhibitory concentration of
CORM-2 (250 μM) significantly increased biofilm pro-
duction in ESBL-producing isolate 1 (p = 0.017) and in
UPEC isolate 2 (p = 0.0058) (Fig. 1). A lower concentra-
tion of CORM-2 (100 μM) had only minor effects on bio-
film formation (data not shown). TG1, a well-established
biofilm-producing E. coli K-12 strain, showed reduced bio-
film formation (p = 0.0045) in response to CORM-2. Bio-
film formation in UPEC isolates 3 and the K-12 strain
MG1655 was not affected by CORM-2 (Fig. 1).
Effect of CORM-2 on bacterial viability within an established
biofilm
We next examined the effect of CORM-2 (500 μM) on
UPEC isolate 2, ESBL-producing isolate 1 and K-12
strain TG1 when grown within an established biofilm
(biofilm formed for 24 h on plastic surface). To quantify
the effects of CORM-2 on bacterial viability a live/dead
viability staining assay and confocal microscopy were
used. Pilot experiments showed that 4 h of exposure to
CORM-2 had minor effect on viability but that the via-
bility of all isolates was clearly reduced by CORM-2 (500
μM) after 24 h of exposure (Fig. 2). The percentage dead
bacteria was 60 ± 16, 61 ± 18 and 85 ± 9 for ESBL iso-
late 1, UPEC isolate 2 and strain TG1, respectively
(Fig. 2, Table 3). Cefotaxime (0.512 μg/ml), a hydrophilic
drug with low permeable [31, 32], killed UPEC isolate 2
(76 ± 8 %) and long filamentous bacteria were observed
by confocal microscopy (Fig. 2). However, no effect on
viability was noted by cefotaxime in ESBL-producing iso-
late 1 or the K-12 strain TG1 (Fig. 2, Table 3). The number
of dead bacteria in DMSO-treated controls was low (Fig. 2,
Table 3). The CO-free molecule Ru(DMSO)4Cl2, used as a
negative control for CORM-2, had similar effects as
DMSO on viability (data not shown).
Effect of CORM-2 on planktonic bacteria in different
growth phases
The antibacterial effect of CORM-2 was compared in
planktonic cultures (ESBL-producing isolate 1, UPEC
isolate 2 and strain TG1) when exposed in the stationary
growth phase or in the exponential growth phase.
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Unexposed controls in the exponential growth phase
showed an increased growth of ~ 1.5 log units during
the 24 h experiment (Fig. 3a). CORM-2 (500 μM)
evoked a fast bactericidal effect, in all isolates, with a re-
duction of bacterial counts by > 3 log units within 4 h
(Fig. 3a). Unexposed controls in the stationary growth
phase showed no increased growth during the 24 h ex-
periment (Fig. 3b). CORM-2 demonstrated a delayed in-
hibitory response in the stationary growth phase, but a
bactericidal effect was found after 24 h (Fig. 3b). Separ-
ate experiments showed that colonies of ESBL-
producing isolate 1 that survived CORM-2 treatment in
the stationary phase, was effectively killed when re-
exposed in the exponential growth phase. Planktonic
cultures of UPEC isolate 2 and the K-12 strain TG1 were
susceptible to cefotaxime with a reduction of growth by
0.32 ± 0.047 and 1.5 ± 0.47 log units, respectively. ESBL-
producing isolate 1 was resistant to cefotaxime.
Effect of CORM-2 following colonization of host bladder
epithelial cells
Separate experiments demonstrated that ESBL-producing
isolates 7 and 9 showed weak colonization of human 5637
bladder epithelial cells, while ESBL isolate 6 showed a
consistent ability to colonize host bladder cells. ESBL iso-
late 1 was excluded in the colonization experiments due
to its gentamycin resistant profile. Infected 5637 bladder
cells were less confluent than uninfected 5637 cells and
approximately 50 % of the cells were viable after 16 h of
infection. Exposure to CORM-2 at 500 μM, but not 250
μM, for 4 h significantly (p = 0.0235) reduced the bacterial
counts of ESBL isolate 6 in the presence of 5637 bladder
cells by approximately 2.5 log units (Fig. 4a). A negative
control for CORM-2, Ru(DMSO)4Cl2, and cefotaxime did
not reduce the bladder cell colonization of ESBL isolate 6
(Fig. 4a). CORM-2 did not affect 5637 bladder cell
confluence or adherence during the 4 h exposure
time. A double immunofluorescence staining proced-
ure was performed to investigate the localization of
colonized bacteria. Bacteria were found both attached
to host bladder cells in the extracellular space and
also intracellular (Fig. 4b-d).
Discussion
Several recent publications highlight the urgent need for
new therapies against multidrug-resistant E. coli [33, 34].
Multidrug-resistant UPEC associated with biofilm on
urinary catheters and within bladder reservoirs are par-
ticularly problematic to eradicate due to a combination
of antibiotic resistance and antibiotic penetration bar-
riers. In the present study, the overall biofilm formation
on plastic abiotic surface was low in the UPEC isolates
compared to the positive control E. coli K-12 strain
TG1. A significant variation in the capacity of different
E. coli isolates to form biofilm exists and both genetic
and environmental factors affect the biofilm phenotype
in a complex manner [35]. Growth medium composition
has significant impact on biofilm formation [35] and
some virulence-associated genes appear to be more
common in E. coli strains with strong biofilm production
[36]. A flow chamber biofilm model system would pos-
sibly have improved the biofilm formation of the UPEC
isolates in the present study. When UPEC isolates with
detectable biofilm formation were exposed to CORM-2
an increased biofilm formation was found in two out of
three isolates, suggesting that increased biofilm produc-
tion may be a defence mechanism against CORM-2. A
previous study performed in an E. coli K-12 strain
showed that CORM-2 increased transcription of several
biofilm-related genes and increased biofilm production
when grown in LB-broth [25]. The two non-pathogenic
Table 2 The basal biofilm production of the different isolates
A540 < 0.1 A540 0.1-1 A540 > 1
ESBL 6, ESBL 7, ESBL 9, UPEC 4, UPEC 5 ESBL 1, UPEC 2, UPEC 3, MG1655 TG1
Basal biofilm production after 24 h in ESBL-producing isolates (ESBL), non-ESBL-producing UPEC isolates (UPEC) and non-pathogenic E. coli K-12 strains (MG1655
and TG1) evaluated by the crystal violet method and measured by absorbance levels (A540). Detectable biofilm production was considered at A540 ≥ 0.1. Mean
values from three to six independent experiments
Fig. 1 The antibacterial effect of CORM-2 on biofilm formation. Effect of
CORM-2 (250 μM) on biofilm formation in non-ESBL-producing UPEC
isolates (UPEC 2 and 3), in an ESBL-producing isolate (ESBL1) and in the
non-pathogenic E. coli K-12 strains MG1655 and TG1. Biofilm formation
was measured by the crystal violet method 18 h after exposure to
CORM-2 and expressed as relative changes compared to untreated
controls. The data are presented as mean ± SEM from at least three
independent experiments. *P < 0.05, **P < 0.01, CORM-2 versus control
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K-12 strains used in our study were unaffected or
showed a reduced biofilm formation when exposed to
CORM-2. Biofilm formation was examined in a concen-
tration (250 μM) that is sub-inhibitory for UPEC [26],
however the growth of planktonic TG1 was reduced at
this concentration (data not shown), which may explain
the impaired ability to form biofilm.
CORMs represent a novel class of antimicrobials and
are so far non-explored agents in the field of eradication
of biofilm growth caused by UPEC. The CO-releasing
profile of CORMs has recently been re-evaluated [20]. It
has been proposed that CORMs are internalized into
bacteria by a Trojan horse mechanism, rather than that
CO diffuses into the cell [22, 37]. CORM-2 was able to
reduce the bacterial viability of ESBL-producing and
non-ESBL-producing UPEC isolates, as well as the K12
strain TG1, when grown within an established biofilm.
Thus, CORM-2 seems able to penetrate biofilm-like
architecture and kill bacteria in biofilms as confirmed by
the live/dead viability assay and confocal microscopy.
The ESBL-producing isolate was resistant to the
cephalosporine antibiotic cefotaxime and, as expected,
cefotaxime did not affect the viability of the ESBL isolate
within an established biofilm. However, exposure to cef-
otaxime reduced the viability of the non-ESBL produ-
cing UPEC isolate and long filamentous bacteria were
visualized by confocal microscopy. Filamentous bacteria
can appear as a consequence of bacterial stress, includ-
ing exposure to beta-lactam antibiotics that through
inhibition of penicillin-binding protein-3 in the peptido-
glycan layer prevents septa formation and cell division
[38]. E. coli strain TG1, with the highest biofilm produc-
tion, was effectively killed (85 %) by CORM-2 but was
Fig. 2 Visualisation of the antibacterial effect of CORM-2 and cefotaxime on established biofilm. Effect of CORM-2 and cefotaxime on bacterial
viability within an established biofilm (biofilm grown for 24 h) evaluated by a live/dead viability staining assay using confocal microscopy. Live
bacteria with intact cell membrane are stained green (SYTO9) and dead bacteria with damaged cell membrane are stained red (propidium
iodine). Photographs show representative areas from the chamber slides; from left to right isolate UPEC isolate 2, ESBL isolate 1 and K-12 strain
TG1 and from top-down a controls, b 24 h CORM-2 (500 μM), c 24 h cefotaxime (0.512 μg/ml). Scale bar = 10 μm. Representative photographs
from three independent experiments are shown
Table 3 Quantitative data from the live/dead viability assay
Stimuli Mean % ± SEM P value
UPEC 2 control 5 ± 2
UPEC 2 CORM-2 61 ± 18 0.0208*
UPEC 2 cefotaxime 76 ± 8 0.0011**
ESBL 1 control 6 ± 2
ESBL 1 CORM-2 60 ± 16 0.0135*
ESBL 1 cefotaxime 5 ± 1
TG1 control 13 ± 2
TG1 CORM-2 85 ± 9 0.0003***
TG1 cefotaxime 4 ± 1
Data show the ratio of dead bacteria (expressed as a percentage) after 24 h
exposure to CORM-2 (500 μM), cefotaxime (0.512 μg/ml) or control (DMSO)
evaluated by a live/dead viability assay. The ratio of dead bacteria was calculated
by manual counting of four randomly selected quadrants (in total covering ¼
from each image) from a representative part of each well. The data are presented
as mean ± SEM. (n = 3) *P < 0.05, **P < 0.01, ***P <0.001; CORM-2 or cefotaxime
versus control
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insensitive to cefotaxime. Cefotaxime is mainly active
against dividing bacteria and has low efficiency for ad-
herent bacteria within a biofilm matrix compared to
planktonic cultures [39]. Our data confirmed that plank-
tonic TG1 cultures, but not bacterial biofilms, were sen-
sitive to cefotaxime. A limitation of this study is that the
biofilm formation by the clinical UPEC isolates was low,
and that the effects of CORM-2 on biofilms may have
been overestimated. However, CORM-2 was effective
against TG-1 biofilms suggesting that CORM-2 is able
to penetrate and reach targets within more mature bio-
films. In agreement with our findings, CORM-2 was
demonstrated to kill a majority of clinical isolates of P.
aeruginosa within an established biofilm [40]. The main
mechanism by which CORM-2 inhibited P. aeruginosa bio-
film appeared to be interference with the respiratory chain
rather than production of reactive oxygen species [40].
Impaired penetration of antibiotics is not the only
mechanism associated with biofilm-related antibiotic re-
sistance. Another characteristic of a biofilm is the pres-
ence of a large subpopulation of bacteria in a dormant
persister state [38]. Bacteria in a dormant state are found
in biofilms and in stationary phase cultures, but not in
cultures in the exponential growth phase. Bacteria that
have entered a dormant state are transiently tolerant to
antibiotics by mechanism such as reduced translation
and cell wall synthesis [41, 42]. The effects of CORM-2
in the exponential and stationary growth phase were in-
vestigated to reveal if slower growing bacteria are more
resistant to CORM-2. CORM-2 reduced bacterial viabil-
ity in the stationary phase, but the inhibition was mark-
edly delayed compared to cultures in the exponential
phase demonstrating that metabolically active bacteria
are more susceptible to CORM-2. Bacteria that survived
the CORM-2 treatment in stationary phase experiments
were killed when re-exposed to CORM-2 in the expo-
nential phase, which suggest that stationary phase bac-
teria may represent dormant persisters with a transient
tolerance to CORM-2. The higher cell density in the sta-
tionary phase may in part explain the delayed efficacy of
CORM-2 in the stationary phase since the effective drug
concentration for each bacterium may be lower.
The 5637 human bladder epithelial cell line was in-
fected with an ESBL-producing isolate and the gentamy-
cin protection assay was used to support intracellular
localization. There are known difficulties in replicating
the conditions required for formation of intracellular
biofilm-like bacterial communities in vitro. However,
UPEC have been shown to invade 5637 bladder epithe-
lial cells but they rarely form large IBC inclusions as
found in superficial bladder facet cells in vivo [11, 43].
The immunofluorescence method used in the present
study, which is able to distinguish between extra- and
intracellular bacteria, demonstrated that the ESBL isolate
could adhere to and invade 5637 bladder epithelial cells.
In agreement with previous studies [11, 43, 44], the
intracellular bacteria were dispersed in the cytosol and
not packed in biofilm-like aggregates. Exposure to
CORM-2 significantly reduced the bacterial counts fol-
lowing bladder epithelial cell colonization. The CO-free
molecule Ru(DMSO)4Cl2 elicited no reduced viability,
verifying that CO is required for the antibacterial effect
of CORM-2. The cell cytotoxicity of CORM-2 (100-500
μM) has previously been observed to be low in 5637
bladder cells and CORM-2 even seemed to have a cyto-
protective effect after 4 h [26]. The exposure time to
CORM-2 was therefore restricted to 4 h in our experi-
ments and no detrimental effects on the cells were ob-
served. It may be argued that cytotoxic effects of
CORM-2 on host bladder cells may enhance its efficacy
against internalized UPEC by disrupting cell barriers.
However, no correlation between 5637 bladder cell cyto-
toxicity and killing of intracellular UPEC by several anti-
biotics was found using a similar cell-culture based assay
as in our study [12]. Nevertheless, we cannot exclude
that some effects of CORM-2 on the host bladder cells
or on bacterial efflux mechanisms from the 5637 cells
Fig. 3 The antibacterial effect of CORM-2 in the exponential and
stationary growth phase. A comparison of the effect of CORM-2
exposure in the exponential growth phase and in the stationary
phase in ESBL isolate 1, UPEC isolate 2 and K-12 strain TG1. a
Cultures were grown to early log phase in MS-broth and then
exposed to CORM-2 (500 μM) or DMSO (control). b Cultures were
grown to stationary phase in MS-broth and then exposed to CORM-
2 (500 μM) or DMSO (control). Growth was calculated as the
numbers of CFU/ml in treated cultures or controls divided by the
number of CFU/ml formed upon the plating of the initial inoculums
and expressed as log CFU/ml. The data are presented as mean ±
SEM from at least three independent experiments. Lower grids show
the detection limit
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contribute to the antibacterial effects of CORM-2 on
colonized bacteria. Taken together, CORM-2 has an in-
teresting antibacterial profile by being effective against
multidrug-resistant UPEC protected in biofilms and in
intracellular reservoirs. It will be of interest to examine
whether CORMs alone or in combination with currently
available antibiotics will have antibacterial effect on
intracellular and persistent UPEC in mouse UTI models.
The search of CORMs with suitable properties for the
delivery of CO and with low cytotoxicity is an ongoing
and active area of research. New CORMs with desirable
therapeutic profiles and clinical compatibility are appear-
ing, but more fundamental knowledge on the chemistry,
cellular targets and molecular biology of CORMs is
needed before these compounds can be used clinically as
antimicrobial agents [20, 45, 46].
The ESBL-producing isolates 6 and 7 belong to the E.
coli ST131 clone that currently represents one of the
most dominant groups of multidrug-resistant E. coli glo-
bally [47]. The ST131 clone, which produces CTX-15, is
thought to be successful due to a combination of
antibiotic resistance and virulence. Here, we show that
ESBL isolate 6 was able to adhere to and invade host
bladder epithelial cells, suggesting that this isolate has a
capacity to form intracellular reservoirs and persist in
the bladder. In agreement, a ST131 reference strain E.
coli EC958 has previously been demonstrated to invade
bladder epithelial cells both in mouse studies [48] and in
vitro studies [49].
Conclusions
This study demonstrates that CORM-2 is able to reduce
the bacterial viability of multidrug-resistant UPEC in
biofilm-like conditions and following colonization of hu-
man bladder epithelial cells. CORMs will be interesting
candidate drugs to investigate further in studies of recur-
rent and chronic UTI caused by multidrug-resistant
UPEC.
Ethics approval and consent to participate
Not applicable.
Fig. 4 The antibacterial effect of CORM-2 on colonization of host cells and localization of colonized bacteria. Quantification and immunofluorescence
staining of ESBL-producing isolate 6 following colonization of 5637 bladder epithelial cells. A gentamycin protection assay was used to support
intracellular growth of the bacteria. a Host bladder 5637 cells were lysed and the lysate serially diluted and plated on TSA plates for quantification of
bacterial count (CFU/ml). Bacterial counts in cell lysate was evaluated after exposure for 4 h to DMSO, the CO-free molecule Ru(DMSO)4Cl2 (500 μM),
cefotaxime (0.512 μg/ml) or CORM-2 (250 and 500 μM). Data are presented as mean ± SEM from four independent experiments. *P < 0.05, CORM-2
versus DMSO. b-d Immunofluorescence staining of ESBL-producing isolate 6 following infection of 5637 bladder epithelial cells. Staining of the bladder
cell nuclei was performed with DAPI and is shown in blue. ESBL isolate 6 are stained b) in red (extracellular) prior to permeabilization, and c) in green
(extracellular and intracellular) after permeabilization. d Merged image of B and C where several intracellular bacteria are seen as green stain (arrows)
and extracellular bacteria are shown as merged red and green (yellow) stain (arrowhead). Scale bar = 10 μm
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